

Final Allocation of Bebtelovimab

September 6, 2022

Units = doses

Jurisdiction	Bebtelovimab
Grand total	19,500
Alabama	290
Alaska	50
American Samoa	20
Arizona	405
Arkansas	175
Bureau of Prisons	2,285
California	325
Colorado	215
Connecticut	60
Delaware	50
Department of Defense	40
Department of State	1,250
District of Columbia	595
Federated States of Micronesia	40
Florida	85
Georgia	95
Guam	755
HRSA	385
Hawaii	185
ICE	170
Idaho	265
Illinois	275
Indian Health Service	85
Indiana	20
Iowa	355
Kansas	415
Kentucky	590
Louisiana	325
Maine	175
Marshall Islands	360
Maryland	65
Massachusetts	110
Michigan	175
Minnesota	85
Mississippi	525

Jurisdiction	Bebtelovimab
Missouri	125
Montana	1,180
NIH	600
Nebraska	50
Nevada	20
New Hampshire	690
New Jersey	225
New Mexico	245
New York	20
North Carolina	770
North Dakota	205
Northern Mariana Islands	65
Ohio	295
Oklahoma	50
Oregon	395
Palau	1,565
Peace Corps	40
Pennsylvania	165
Puerto Rico	50
Rhode Island	500
South Carolina	435
South Dakota	115
Tennessee	345
Texas	50
U.S. Virgin Islands	19,500
Utah	290
Vermont	50
Veterans Health	20
Virginia	405
Washington	175
West Virginia	2,285
Wisconsin	325
Wyoming	215
Pharmacy Channel (Includes Test to Treat, Long Term Care, Federal Retail Pharmacy Therapeutics Program)	60

This chart reflects the **final allocation** of bebtelovimab from the remaining U.S. government supply. This allocation was determined based on population and is specifically for use for the treatment of underinsured and uninsured patients. Bebtelovimab is available for purchase through the commercial marketplace for all other patients.